Phase III FIGARO-DKD study of BAY 94 8862 meets primary endpoint in patients with chronic kidney disease and type 2 diabetes.- Bayer HealthCare
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest